Friday, October 9th, 2020

08:30–08:40 Welcome

SESSION I – Smoldering myeloma
Chair: TBA

08:40-08:45 Introduction TBA
08:45-09:00 Clonal evolution in smoldering myeloma Madhav V. Dhodapkar (Atlanta)
09:00-09:05 Discussion TBA
09:05-09:20 High-risk smoldering: what is the exact definition? Irene Ghobrial (Boston)
09:20-09:25 Discussion TBA
09:25-09:40 Clinical trials Maria-Victoria Mateos (Salamanca)
09:40-09:45 Discussion TBA
09:45-09:55 Selected brief oral communication TBA
09:55-09:58 Discussion TBA
10:00-10:30 Panel discussion TBA

10:30-11:00 Coffee Break

SESSION II – Diagnosis of multiple myeloma
Chair: TBA

11:00-11:05 Introduction TBA
11:05-11:20 Diagnostic criteria and initial workup Shaji Kumar (Rochester)
11:20-11:25 Discussion TBA
11:25-11:40 Genetics and risk assessment Hervé Avet-Loiseau (Toulouse)
11:40-11:45 Discussion TBA
11:45-12:00 Frailty assessment at diagnosis Alessandra Larocca (Turin)
12:00-12:05 Discussion TBA
SESSION III – Frontline therapy in patients not eligible for autologous stem cell transplantation
Chair: TBA

14:35-14:40  Introduction  TBA
14:40-14:55  Overview phase 3 trials and newly approved treatments  Xavier Leleu (Lille)
14:55-15:00  Discussion
15:00-15:15  Fit vs Frail: the European point of view  Sonja Zweegman (Amsterdam)
15:15-15:20  Discussion
15:20-15:35  Fit vs Frail: the point of view in the US  Hira Mian (Hamilton)
15:35-15:40  Discussion
15:40-15:50  Selected brief oral communication  Speaker
15:50-15:53  Discussion
15:55-16:25  Panel discussion

16:25-16:55  Coffee break

SESSION IV – Frontline therapy in patients eligible for autologous stem cell transplantation
Chair: TBA

16:55-17:00  Introduction  TBA
17:00-17:15  Overview of European trials  Philippe Moreau (Nantes)
17:15-17:20  Discussion
17:20-17:35  US point of view on new trials (including explanation of why HSCT is not proposed frontline)  Paul Richardson (Boston)
17:35-17:40  Discussion
17:40-17:55  Maintenance therapy  Graham Jackson (Newcastle)
17:55-18:00  Discussion
18:00-18:10  Selected brief oral communication  Speaker
18:10-18:13  Discussion
18:15-18:45  Panel discussion and/or controversial debates
18:45  Mentored Poster Walks and Welcome Get Together stand up buffet dinner

Saturday, October 10th, 2020

09:00-10:00  Possible slot for a satellite symposium

09:00-10:00  3 Simultaneous Meet the Expert sessions (non-clinical)

10:00-10:25  Coffee break

SESSION V – MRD and the microenvironment
Chair: TBA

10:25-10:30  Introduction  TBA
10:30-10:45  MRD and imaging  Elena Zamagni (Bologna)
10:45-10:50  Discussion
10:50-11:05  MRD and immune profiling (differences in terms of response)  Bruno Paiva (Pamplona)
11:05-11:10  Discussion
11:10-11:25  How MRD assessment will impact clinical management  Jesus San Miguel (Pamplona)
11:25-11:30  Discussion
11:30-11:40  Selected brief oral communication  Speaker
11:40-11:43  Discussion
11:45-12:15  Panel discussion

12:15-13:55  Lunch

12:45-13:45  Possible slot for a satellite symposium

SESSION VI – Relapsed multiple myeloma
Chair: TBA

13:55-14:00  Introduction  TBA
14:00-14:15  How to sequence in 1st and 2nd relapse?  Meletios Dimopoulos (Athens)
14:15-14:20  Discussion
14:20-14:35  Beyond 2nd relapse  Saad Usmani (Charlotte)
14:35-14:40  Discussion
14:40-14:55  Overview immune therapies?  Noopur Raje (Boston)
14:55-15:00  Discussion
15:00-15:10  Brief Oral Communication  Speaker
15:10-15:13  Discussion
SESSION VII – The future: recent clinical trials in relapse
Chair: TBA

16:10-16:15 Introduction TBA
16:15-16:30 Novel targeted therapies (not immune) Shaji Kumar (Rochester)
16:30-16:35 Discussion
16:35-16:50 Novel immunotherapies (part 1) Hermann Einsele (Würzburg)
16:50-16:55 Discussion
16:55-17:10 Novel immunotherapies (part 2) Sagar Lonial (Atlanta)
17:10-17:15 Discussion
17:15-17:25 Brief Oral Communication Speaker
17:25-17:28 Discussion
17:30-18:00 Panel discussion and/or controversial debates

18:10-19:10 Possible slot for a satellite symposium

Sunday, October 11th, 2020

07:30-8:30 3 Simultaneous Breakfast Meet the Expert Sessions (Clinical)

SESSION VIII – Data management issues
Chair: TBA

08:35-08:40 Introduction TBA
08:40-08:55 Access to innovative drugs: pharma-academia cooperation Mohamad Mohty (Paris)
08:55-09:00 Discussion
09:00-09:15 iStopMM-a nationwide screening for MGUS and myeloma and early treatment of smoldering myeloma Sigurdur Kristinsson (Reykjavik)
09:15-09:20 Discussion
09:20-09:35 Bureaucracy is strangling clinical research Steven Le Gouill (Nantes)
09:35-09:40 Discussion
09:40-09:55 EMA vs FDA approvals: differences, why? Kyriaki Tzogani (Amsterdam)
09:55-10:00 Discussion
10:00-10:30 Panel discussion (and short communications ?)
SESSION IX – Plasma cell disorders
Chair: TBA

10:55-11:00 Introduction
TBA

11:00-11:15 Waldenstrom’s disease
Jorge Castillo (Boston)

11:15-11:20 Discussion

11:20-11:35 POEMS
Arnaud Jaccard (Limoges)

11:35-11:40 Discussion

11:40-11:55 Monoclonal gammopathy of clinical significance
Jean-Paul Fermand (Paris)

11:55-12:00 Discussion

12:00-12:15 Amyloidosis
Giampaolo Merlini (Pavia)

12:15-12:20 Discussion

12:20-12:50 Panel discussion (and short communications ?)

12:50-13:00 Closing Remarks

MEETING CLOSURE